Innate Pharma S.A.

ENXTPA:IPH Stock Report

Market Cap: €155.7m

Innate Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of IPH?
Owner TypeNumber of SharesOwnership Percentage
Institutions1,456,8331.8%
Individual Insiders2,004,8672.48%
VC/PE Firms6,389,4067.89%
Public Companies17,303,04621.4%
General Public53,796,63066.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 33.51% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.1%
Novo Nordisk A/S
9,817,546€18.9m0%no data
9.25%
AstraZeneca PLC
7,485,500€14.4m0%no data
7.89%
Bpifrance Participations SA
6,389,406€12.3m0%0.11%
0.91%
Herve Brailly
739,784€1.4m0%no data
0.78%
Mondher Mahjoubi
631,088€1.2m0%no data
0.61%
Amundi Asset Management SAS
491,602€945.8k0%no data
0.4%
Saint Olive Gestion
320,000€615.7k0%0.07%
0.26%
Eric Vivier
210,228€404.5k0%no data
0.26%
Française Asset Management
209,000€402.1k0%0.14%
0.24%
Yannis Morel
194,192€373.6k0%no data
0.11%
Optiver US LLC, Asset Management Arm
86,788€167.0k-0.65%no data
0.096%
Exchange Traded Concepts, LLC
77,350€148.8k-10.3%no data
0.09%
Gilles Brisson
73,059€140.6k0%no data
0.08%
Envestnet Asset Management, Inc.
64,826€124.7k7.78%no data
0.077%
Odile Belzunce
62,249€119.8k0%no data
0.076%
Haussmann Investissement Managers
61,276€117.9k0%1.64%
0.054%
Morgan Stanley, Investment Banking and Brokerage Investments
43,524€83.7k0%no data
0.047%
Odile Laurent
37,979€73.1k0%no data
0.033%
Dimensional Fund Advisors LP
26,317€50.6k0%no data
0.031%
Irina Staatz-Granzer
25,100€48.3k0%no data
0.031%
Claresco Finance
25,000€48.1k0%0.02%
0.026%
Citadel Advisors LLC
21,267€40.9k-9.61%no data
0.014%
Frederic Lombard
11,362€21.9k0%no data
0.012%
Welzia Management SGIIC SA
9,940€19.1k0%0.03%
0.011%
Nicola Beltraminelli
9,246€17.8k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 09:45
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Innate Pharma S.A. is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Olga SmolentsevaBryan Garnier & Co
Yigal NochomovitzCitigroup Inc
Michael Thomas CooperEdison Investment Research